Hormonal
Prior endurance or strength training history attenuates the acute phosphorylation of AMPK and Akt signaling pathways in response to divergent exercise stimuli, indicating that chronic adaptation blunts specific early signaling responses to non-habitual training modes.
If you are already well-trained in one type of exercise (e.g., running or weightlifting), switching to a different type (e.g., lifting or running) will not trigger the same intense initial signaling response as a beginner would experience. This does not mean the new exercise is ineffective; your body is simply more efficient. Focus on consistency and progressive overload rather than chasing acute 'burn' or signaling markers, as your adapted muscle handles stress differently.
Prior training history blunts the normal exercise-specific increase in AMPK phosphorylation... Prior training history blunts the normal exercise-specific increase in PGC-1alpha protein expression... prior endurance- or strength-training appears to attenuate some of the signaling specific responses involved in the adaptation to single mode training.
Why this rating
The study uses a rigorous crossover design with well-trained human subjects and statistically significant p-values for phosphorylation changes, though it is a single acute bout study.
Source
Early signaling responses to divergent exercise stimuli in skeletal muscle from well‐trained humans
Vernon G. Coffey et al. · The FASEB Journal · 2005
DOI 10.1096/fj.05-4809fje
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →